Trial Profile
A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2019
Price :
$35
*
At a glance
- Drugs NVR 3778 (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novira Therapeutics
- 05 Jan 2019 Results published in the Gastroenterology
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 15 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.